Soňa Kiňová, Michal Koreň
Neuroendocrine tumours (NETs) are uncommon malignancies with a very diverse presentation and prognosis. They occur
most often in the gastrointestinal tract. The clinical picture is modified by localisation of tumours, typical is symptomatology
from hormonal overproduction such as a carcinoid syndrome, hypoglycaemia or resistant peptic ulcers of
the gastroduodenum. Patients with NETs frequently have circulating tumour biomarkers that may aid in the diagnosis
and help with prognostication. The most commonly used and best studied marker is chromogranin A, which appears to
reflect the tumour mass and is useful at the time of diagnosis, and to monitor for recurrence after resection and to assess
response to systemic therapy. Multiple other biomarkers are in use, like pancreastatin, neurokinin A.